SWOT Analysis for Eledon Pharmaceuticals Inc

Relative Outperformance versus Industry over 1 Week
Significant (over 30%) distance from 52 week high
Relative Outperformance versus Industry over 1 Year
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Company with Low Debt
Stock with Low PE (PE < = 10)
Highest Recovery from 52 Week Low

Stocks with Quarter Change % less than Industry
Oversold by Money Flow Index (MFI)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Top Losers
Low Piotroski Score : Companies with weak financials
Annual net profit declining for last 2 years
Book Value Per Share deteriorating for last 2 years
Weak performer : Stock lost more than 20% in 1 month
RSI indicating price weakness
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter

Forecaster Consensus Estimates: Stocks with Strong Buy Calls from Analysts
Mutual Funds Increased Shareholding in Past Month
Institutions increasing their shareholding
Mutual Funds Increased Shareholding over the Past Two Months
MFs increased their shareholding last quarter
Mf buying for 2 months